Supplementary
GABRD, GABRG1, GABRG2, GABRA2, GABRA1, GABRA4, GABRB2, GABRB1, GABRA5
GO:0016917~GABA receptor activity 9 2.10E-16 2.55E-13 GABRD, GABRG1, GABRG2, GABRA2, GABRA1, GABRA4, GABRB2, GABRB1, GABRA5 GO:0034707~chloride 10 3.37E-15 3.59E-12 GABRD, GABRG1, FXYD1, GABRG2, GABRA2, GABRA1, GABRA4, GABRB2, GABRB1, GABRA5
www.aging-us.com 2 AGING Supplementary Table 3 . ADMET (Adsorption, Distribution, Metabolism and Excretion) and toxicity properties of compounds. 1  ZINC03918087  4  3  2  1  0  0  2  ZINC58661275  3  0  2  0  1  0  3  ZINC06718723  3  0  3  0  0 
Number

Compounds BBB level a Absorption b Solubility c Hepatotoxicity d CYP2D6 e PPB Level f
a Blood Brain Barrier level: 0 (Very high penetrant); 1 (High); 2 (Medium); 3 (Low); 4 (Undefined); b Human intestinal absorption level: 0 (good); 1 (moderate); 2 (poor); 3 (very poor); c Aqueous solubility level: 0 (extremely low); 1 (very low, but possible); 2 (low); 3 (good); d Hepatotoxicity: 0 (Nontoxic); 1 (Toxic); e Cytochrome P450 2D6 level: 0 (Non-inhibitor); 1 (Inhibitor); f Plasma Protein Binding: 0 (Binding is <90%); 1 (Binding is>90%); 2 (Binding is >95%). 
Toxicity properties of compounds
